author-photo

Amanda L. Hudson

University of Sydney

35

Papers

297

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
Are In Vitro Human Blood-Brain-Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
ALK‐Rearranged Non‐Small Cell Lung Cancer in 2020: Real‐World Triumphs in an Era of Multigeneration ALK‐Inhibitor Sequencing Informed by Drug Resistance Profiling

2020 Oncologist
Show All
- Source
- Cite
- Save
Citations (3)
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.

2020 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (7)
P2.01-11 ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib with Crizotinib After Disease Progression

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
GENE-20. IDENTIFYING POTENTIAL GENES AND MECHANISMS DRIVING IDH-MUTANT GLIOMA PROGRESSION AND RECURRENCE THROUGH RNA-SEQUENCING

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
COMP-15. MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
P1.01-24 Preclinical Proteomic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The intertwined fates of inflammation and coagulation in glioma

2018 Mammalian Genome
Show All
- Source
- Cite
- Save
Citations (4)